Takaaki Ono, Akihiro Takeshita, Yuji Kishimoto, Hitoshi Kiyoi, Masaya Okada, Takahiro Yamauchi, Nobuhiko Emi, Kentaro Horikawa, Mitsuhiro Matsuda, Katsuji Shinagawa, Fumihiko Monma, Shigeki Ohtake, Chiaki Nakaseko, Masatomo Takahashi, Yukihiko Kimura, Masako Iwanaga, Norio Asou, Tomoki Naoe and for The Japan Adult Leukemia Study Group Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell counts Cancer Science 105
Version of Record online: 9 JAN 2014 | DOI: 10.1111/cas.12319
We assessed clinical significance of CD56 antigen in acute promyelocytic leukemia (APL) treated with all-trans retinoic acid and chemotherapy. Our study showed a significant correlation of CD56 expression with lower platelet counts and severe disseminated intravascular coagulation. Among patients with initial white blood cell counts of 3.0 × 109/L or more, event-free survival (EFS) and cumulative incidence of relapse in CD56+ APL were significantly worse, and in multivariate analysis, CD56 expression was an unfavorable prognostic factor for EFS.
Complete the form below and we will send an e-mail message containing a link to the selected article on your behalf
Required = Required Field